Malignant Hematologist focused on Lymphoma

Locations; Raleigh, NC

The Division of Hematologic Malignancies & Cellular Therapy at Duke Health is seeking a Hematologist/Oncologist with a focus on Chronic Lymphoma to join our nationally recognized blood cancer program.

We are particularly interested in physicians with several years of experience beyond fellowship who are passionate about academic medicine, clinical research, and education, while delivering exceptional patient-centered care.

Position Opportunities:

Durham – Duke University Medical Center (Academic Focus):

• Outpatient clinic and infusion services at Duke Blood Cancer Center
• Inpatient rounding on the blood cancer service
• Active participation in clinical research and clinical trials
• Teaching fellows, residents, and medical students

Raleigh – Duke Raleigh Hospital Cancer Center (Clinical Growth Focus):

• Build and expand a lymphoma-focused clinical practice
• Collaborate closely with Duke Blood Cancer Center
• Participate in tumor boards and clinical trial enrollment
• Outpatient clinic and infusion services
• Inpatient consultation on Hematology/Oncology service

Upcoming new construction in Wake County (Cary, Garner, and beyond)

• Build and expand a lymphoma-focused clinical practice
• Inpatient consultation on Hematology/Oncology service at Duke Raleigh
• Practice will be mostly outpatient for 3-4 years until the hospital is built on this same campus

Qualifications:

• Board Certified/Board Eligible in Hematology and/or Oncology
• Demonstrated focus in lymphoma (chronic lymphoma is the greatest need)
• Strong interest in academic advancement, research, and multidisciplinary care

Compensation & Benefits:
Faculty title and salary will be commensurate with experience and role focus. Duke Health offers a competitive compensation model that rewards both clinical productivity and academic achievement, along with comprehensive benefits including retirement, CME, relocation, and tuition assistance for dependents.

About the Triangle:
Living in Durham, Raleigh, and Chapel Hill means enjoying a dynamic lifestyle with an award-winning culinary scene, diverse cultural experiences, and year-round events. With excellent educational opportunities ranging from top-ranked schools to prestigious universities, the region offers something for every stage of life.

Duke is an Equal Opportunity Employer committed to providing employment opportunity without regard to an individual's age, color, disability, gender, gender expression, gender identity, genetic information, national origin, race, religion, (including pregnancy and pregnancy related conditions), sexual orientation, or military status.

Duke aspires to create a community built on collaboration, innovation, creativity, and belonging. Our collective success depends on the robust exchange of ideas—an exchange that is best when the rich diversity of our perspectives, backgrounds, and experiences flourishes. To achieve this exchange, it is essential that all members of the community feel secure and welcome, that the contributions of all individuals are respected, and that all voices are heard. All members of our community have a responsibility to uphold these values.

PLEASE NOTE: To be considered for this position, please attach your CV, select SUBMIT APPLICATION, and complete the application questions.

The mission of the Duke Division of Hematologic Malignancies and Cellular Therapy is to promote health and improve lives by preventing, diagnosing, and treating blood cancer and other life threatening diseases through integrated innovative and holistic patient care, education, and research.

The Division is integrated with the Duke Cancer Institute, one of 69 National Cancer Institute-designated Comprehensive Cancer Centers.

The Hematologic Malignancies and Cellular Therapy (HMCT) Program is a multidisciplinary basic, translational and clinical research program whose overall goal is to improve outcomes for patients with hematologic malignancies. The broad, long-term goal of the HMCT Program is to build on and extend the current knowledge in the fields of leukemia, lymphoma, myeloma, hematopoietic cell transplantation, and immunotherapy, and to develop and implement novel strategies for improving therapeutic results in these patients through a collaborative and integrated approach involving all the investigators in the program.